Other studies have shown that TAMs confer poor prognosis in prostate cancer, likely through their ability to promote metastasis and progression through the CCL2-CCR2 and CCL22-CCR4 axes [17,35,36,37,38]. This evidence concerns the gene CCR4 and prostate carcinoma.